Fort Washington Investment Advisors Inc. OH Sells 35,220 Shares of Haemonetics Co. (NYSE:HAE)

Fort Washington Investment Advisors Inc. OH trimmed its position in shares of Haemonetics Co. (NYSE:HAE) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 274,130 shares of the medical instruments supplier’s stock after selling 35,220 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned approximately 0.55% of Haemonetics worth $21,404,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HAE. Wellington Management Group LLP lifted its position in Haemonetics by 9.5% during the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after buying an additional 363,702 shares during the period. Royce & Associates LP lifted its position in Haemonetics by 2.6% during the 3rd quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier’s stock valued at $97,304,000 after acquiring an additional 30,868 shares during the period. Geode Capital Management LLC lifted its position in Haemonetics by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock valued at $95,986,000 after acquiring an additional 21,547 shares during the period. Thrivent Financial for Lutherans grew its holdings in Haemonetics by 29.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after purchasing an additional 250,833 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Haemonetics by 6.3% in the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock worth $80,972,000 after purchasing an additional 57,665 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 2.5 %

Shares of HAE stock opened at $73.33 on Thursday. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The company has a 50 day simple moving average of $81.35 and a two-hundred day simple moving average of $80.09. The stock has a market cap of $3.68 billion, a P/E ratio of 30.43, a P/E/G ratio of 1.14 and a beta of 0.41. Haemonetics Co. has a 12 month low of $69.29 and a 12 month high of $97.97.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.99 earnings per share. On average, research analysts expect that Haemonetics Co. will post 4.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

HAE has been the subject of a number of recent research reports. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective for the company. Barrington Research reaffirmed an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a research report on Wednesday, December 4th. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a research report on Friday, November 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $112.00 price target on shares of Haemonetics in a report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $108.78.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.